Clear All
765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9150 Daunorubicin Daunorubicin Hydrochloride 10 mg Chemotherapy Antitumor Antibiotic Anthracycline No 1996 Jan 1, 1986 In Use
J9118 Calaspargase pegol-mknl Asparlas 10 units Chemotherapy Miscellaneous Agent Enzyme No 2018 Oct 1, 2019 In Use
J9313 Moxetumomab-pasudotox-tdfk Lumoxiti 0.01mg Immunotherapy Drug Antibody Conjugate CD22 No 2018 Oct 1, 2019 In Use
J9292 Pemetrexed dipotassium Pemetrexed Dipotassium 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2025 Jan 1, 2025 In Use
Q5115 Rituximab-abbs Truxima 10mg Immunotherapy Monoclonal Antibody CD20 No 2018 Jul 1, 2019 In Use
J9382 Zenocutuzumab-zbco Bizengri 1mg Immunotherapy Bispecific Antibody HER2, HER3 No 2024 Jul 9, 2025 In Use
S0091 Granisetron Hydrochloride Granisol [DSC], Sancuso, Sustol, Kytril 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1993 Jan 1, 2002 In Use
C9474 Irinotecan Onivyde 1 mg Chemotherapy Topoisomerase I Inhibitor Campothecin Analogs No 1996 Jan 1, 2016 In Use
NA Ruxolitinib Jakafi 20 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
J9273 Tisotumab vedodin-tftv Tivdak 1mg Immunotherapy Drug Antibody Conjugate Tissue factor No 2021 Mar 25, 2022 In Use
J1190 Dexrazoxane Zinecard 250 mg Ancillary Therapy Chemoprotective Detoxifying Agent No 1995 Jan 1, 2007 In Use
NA Dinutuximab Unituxin 3.5 mg/mL Immunotherapy Monoclonal Antibody GD-2 No 2015 In Use
J9171 Docetaxel Taxotere 1 mg Chemotherapy Antimitotic Agent Taxane No 1996 Jan 1, 2010 In Use
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
J9262 Omacetaxine Synribo 0.01 mg Chemotherapy Plant Alkaloid BCR-ABL No 2012 Jan 1, 2014 In Use
Q5123 Rituximab-arrx Riabni 10mg Immunotherapy Monoclonal Antibody CD20 No 2021 Jul 23, 2021 In Use
NA Dostarlimab Jemperli 50mg Immunotherapy Checkpoint Inhibitor PD-1 Yes 2021 In Use
J9359 Loncastuximab tesirine-lpyl Zynlonta 0.075mg Immunotherapy Drug Antibody Conjugate CD19 No 2021 Mar 25, 2022 In Use
J9061 Amivantamab Rybrevant 2mg Immunotherapy Monoclonal Antibody EGFR, MET No 2021 Jan 26, 2022 In Use
J1260 Dolasetron Mesylate Anzemet 10 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1997 Jan 1, 2000 In Use
NA Nintedanib Ofev 100 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Yes 2014 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
NA Vandetanib Caprelsa 300 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Palbociclib Ibrance 125 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.